U.S. FDA approves another Sanofi drug for rare muscle disorder Pompe disease | Reuters
Sanofi Secures FDA Nod in Late-Onset Pompe Disease | BioSpace
Lumizyme | The Pompe Registry
Sanofi posts 'better than expected' Q2 results, analysts say
Sanofi Aventis – GM IMPIANTI
Sanofi invests US$150m to acquire oral Pompe disease drug candidate from Maze Therapeutics | HealthCare Middle East & Africa Magazine
Sanofi finds new Pompe disease therapy in Maze | pharmaphorum
Sanofi su LinkedIn: Malattia di Fabry
Sanofi Launched Advanced Treatment for Pompe Disease | CCI France Taiwan
Pompe - Climbing Stairs
Sanofi Genzyme goes to Phase III with Neuromuscular Disease
Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug - MedCity News
FDA aprueba Nexviazyme® de Sanofi Genzyme, una nueva e importante opción de tratamiento para la enfermedad de Pompe
Sanofi Genzyme goes to Phase III with Neuromuscular Disease
Sanofi Italia on X: "La nostra ricerca sulle malattie rare non si ferma: sono 39 le presentazioni che terremo in questi giorni al @WORLDSymposia 2022 a San Francisco. Tra queste, anche nuovi
BioCentury - Aug. 6 Quick Takes: Sanofi gains FDA approval for Pompe therapy